IKT insider buying and SEC filings, explained
Inhibikase Therapeutics, Inc. · CIK 1750149
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Nov 21, 2025 | Other purchase | Frank M. Sands (10% owner) bought 2,068,965 Common Stock at $1.45 ($3.0M) in a public offering. Holdings up 19% to 13,018,965 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 2 other reporting owners. | SEC filing Filed Nov 24, 2025 |
15 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow IKT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.